Related Experiment Videos
Multimodality Therapy for Esophageal Cancer.
1Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der TU Munchen, D-81675 Munchen, Germany.
The Oncologist
|January 1, 1996
Summary
Neoadjuvant therapy for esophageal cancer shows survival benefits only for locally advanced tumors, not for potentially resectable ones. Further research is needed for better response prediction and less toxic regimens.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Adjuvant and neoadjuvant therapies are increasingly used for esophageal cancer.
- Postoperative adjuvant therapy (radiation/chemotherapy) after complete resection does not improve survival.
- The role of neoadjuvant preoperative therapy for esophageal adenocarcinoma and squamous cell carcinoma requires further investigation.
Purpose of the Study:
- To evaluate the effectiveness of neoadjuvant therapy in esophageal cancer management.
- To determine survival benefits in patients with potentially resectable versus locally advanced tumors.
- To identify patient subgroups that benefit from neoadjuvant treatment.
Main Methods:
- Review of randomized prospective trials and controlled trials on neoadjuvant and adjuvant therapies for esophageal cancer.
- Analysis of outcomes comparing primary resection with multimodal approaches (including neoadjuvant therapy).
- Assessment of response rates and survival data based on tumor resectability and response to neoadjuvant treatment.
Main Results:
- Adjuvant therapy post-resection offers no survival advantage.
- Neoadjuvant therapy does not improve survival for potentially resectable locoregional tumors compared to primary resection.
- Neoadjuvant therapy significantly increases resectability and complete tumor removal chances in locally advanced tumors.
- Only patients showing objective clinical or histopathological response benefit from neoadjuvant therapy.
- Combined radiochemotherapy enhances response rates but increases postoperative morbidity/mortality compared to chemotherapy alone.
Conclusions:
- Neoadjuvant therapy is most beneficial for locally advanced esophageal cancer, improving resectability.
- Patient selection based on predicted response is crucial for successful neoadjuvant treatment.
- Current neoadjuvant therapy should be conducted in experienced centers within clinical trials.
- Development of more effective, less toxic preoperative regimens and predictive response factors is essential.